The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis
Objectives. Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metformin (MET) have markedly antiobesity effects in overweight/obese polycystic ovary syndrome (PCOS) patients. However, there was no literature to compare the antiobesity effects of these two medicines. Therefore, a systemat...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2021/6616693 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555236763369472 |
|---|---|
| author | Xiaorui Lyu Taibiao Lyu Xue Wang Huijuan Zhu Hui Pan Linjie Wang Hongbo Yang Fengying Gong |
| author_facet | Xiaorui Lyu Taibiao Lyu Xue Wang Huijuan Zhu Hui Pan Linjie Wang Hongbo Yang Fengying Gong |
| author_sort | Xiaorui Lyu |
| collection | DOAJ |
| description | Objectives. Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metformin (MET) have markedly antiobesity effects in overweight/obese polycystic ovary syndrome (PCOS) patients. However, there was no literature to compare the antiobesity effects of these two medicines. Therefore, a systematic review and meta-analysis were conducted in our present study to evaluate the antiobesity effects of GLP-1RAs either as monotherapy or combined with MET in comparison with MET alone in overweight/obese PCOS patients. Methods. All randomized controlled trials (RCTs) which reported the efficacy of GLP-1RAs and MET in overweight/obese PCOS patients in Medline (from Pubmed), Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus databases were independently searched by two reviewers. The random-effect model was used to pool data extracted from the included literature. The weighted mean difference (WMD) and 95% confidence interval (CI) were used to present the meta-analysis results (PROSPERO registration number: CRD42020173199). Results. A total of eight eligible RCTs were finally enrolled in our meta-analysis from the 587 retrieved literature. The results showed that GLP-1RAs alone or combined with MET was associated with a greater weight loss (N = 318, WMD = −2.61, 95% CI: −3.51 to −1.72, P≤0.001, I2 = 77.5%), more obvious reduction of waist circumference (N = 276, WMD = −3.46, 95% CI: −4.36 to −2.56, P≤0.001, I2 = 0.0%), and body mass index (BMI) (N = 318, WMD = −0.93, 95% CI: −1.60 to −0.26, P=0.007, I2 = 84.9%) in overweight/obese PCOS patients when compared with MET alone. Further sensitivity analysis demonstrated that the meta-analysis results of the efficacy differences in terms of body weight, waist circumference, and BMI were relatively stable and reliable. Conclusion. Our meta-analysis demonstrated that the antiobesity effect of GLP-1RAs alone or combined with MET was superior to MET alone in terms of weight loss, the reduction of waist circumference, and BMI. More large-scale, high-quality RCTs are needed to further confirm these results in PCOS patients. |
| format | Article |
| id | doaj-art-3c483e76bd6e4a158146f8283869b3ca |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-3c483e76bd6e4a158146f8283869b3ca2025-02-03T05:49:15ZengWileyInternational Journal of Endocrinology1687-83371687-83452021-01-01202110.1155/2021/66166936616693The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-AnalysisXiaorui Lyu0Taibiao Lyu1Xue Wang2Huijuan Zhu3Hui Pan4Linjie Wang5Hongbo Yang6Fengying Gong7Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100730, ChinaDepartment of Rheumatology and Clinical Immunology, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, ChinaKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100730, ChinaKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100730, ChinaKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100730, ChinaKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100730, ChinaKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100730, ChinaKey Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing 100730, ChinaObjectives. Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metformin (MET) have markedly antiobesity effects in overweight/obese polycystic ovary syndrome (PCOS) patients. However, there was no literature to compare the antiobesity effects of these two medicines. Therefore, a systematic review and meta-analysis were conducted in our present study to evaluate the antiobesity effects of GLP-1RAs either as monotherapy or combined with MET in comparison with MET alone in overweight/obese PCOS patients. Methods. All randomized controlled trials (RCTs) which reported the efficacy of GLP-1RAs and MET in overweight/obese PCOS patients in Medline (from Pubmed), Embase, Cochrane Central Register of Controlled Trials, Web of Science, and Scopus databases were independently searched by two reviewers. The random-effect model was used to pool data extracted from the included literature. The weighted mean difference (WMD) and 95% confidence interval (CI) were used to present the meta-analysis results (PROSPERO registration number: CRD42020173199). Results. A total of eight eligible RCTs were finally enrolled in our meta-analysis from the 587 retrieved literature. The results showed that GLP-1RAs alone or combined with MET was associated with a greater weight loss (N = 318, WMD = −2.61, 95% CI: −3.51 to −1.72, P≤0.001, I2 = 77.5%), more obvious reduction of waist circumference (N = 276, WMD = −3.46, 95% CI: −4.36 to −2.56, P≤0.001, I2 = 0.0%), and body mass index (BMI) (N = 318, WMD = −0.93, 95% CI: −1.60 to −0.26, P=0.007, I2 = 84.9%) in overweight/obese PCOS patients when compared with MET alone. Further sensitivity analysis demonstrated that the meta-analysis results of the efficacy differences in terms of body weight, waist circumference, and BMI were relatively stable and reliable. Conclusion. Our meta-analysis demonstrated that the antiobesity effect of GLP-1RAs alone or combined with MET was superior to MET alone in terms of weight loss, the reduction of waist circumference, and BMI. More large-scale, high-quality RCTs are needed to further confirm these results in PCOS patients.http://dx.doi.org/10.1155/2021/6616693 |
| spellingShingle | Xiaorui Lyu Taibiao Lyu Xue Wang Huijuan Zhu Hui Pan Linjie Wang Hongbo Yang Fengying Gong The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis International Journal of Endocrinology |
| title | The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis |
| title_full | The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis |
| title_fullStr | The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis |
| title_short | The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis |
| title_sort | antiobesity effect of glp 1 receptor agonists alone or in combination with metformin in overweight obese women with polycystic ovary syndrome a systematic review and meta analysis |
| url | http://dx.doi.org/10.1155/2021/6616693 |
| work_keys_str_mv | AT xiaoruilyu theantiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT taibiaolyu theantiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT xuewang theantiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT huijuanzhu theantiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT huipan theantiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT linjiewang theantiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT hongboyang theantiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT fengyinggong theantiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT xiaoruilyu antiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT taibiaolyu antiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT xuewang antiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT huijuanzhu antiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT huipan antiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT linjiewang antiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT hongboyang antiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis AT fengyinggong antiobesityeffectofglp1receptoragonistsaloneorincombinationwithmetformininoverweightobesewomenwithpolycysticovarysyndromeasystematicreviewandmetaanalysis |